Neuphoria Therapeutics Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	14.99	15.65	-	-	0.18	-
Revenue Growth (YoY)	2161.41%	-	-	-	-	-
Gross Profit	14.99	15.65	-	-	0.18	-
Selling, General & Admin	7.47	7.77	8.47	8.91	7.86	5.44
Research & Development	9.85	9.01	9.42	13.07	11.04	4.32
Other Operating Expenses	1.24	-	-	-	-	-
Total Operating Expenses	18.56	16.78	17.89	21.98	18.9	9.76
Operating Income	-3.57	-1.13	-17.89	-21.98	-18.72	-9.76
Interest Income	0.41	0.17	0.22	0.32	0.01	0
Interest Expense	-	-	-	-	-0.03	-1.08
Other Non-Operating Income (Expense)	-2.8	0.12	2.09	0.14	-0.4	3.2
Total Non-Operating Income (Expense)	-2.39	0.29	2.31	0.46	-0.43	2.13
Pretax Income	-5.96	-0.84	-15.58	-21.52	-19.14	-7.64
Provision for Income Taxes	-0.42	-0.47	-0.09	-0.14	-0.13	-0.14
Net Income	-5.66	-0.37	-15.49	-21.38	-15.01	-6.52
Net Income to Common	-5.66	-0.37	-15.49	-21.38	-15.01	-6.52
Shares Outstanding (Basic)	3	2	1	1,469	1,353	1,008
Shares Outstanding (Diluted)	3	2	1	1,469	1,353	1,008
Shares Change (YoY)	123.33%	95.01%	-99.94%	8.53%	34.31%	-
EPS (Basic)	-3.24	-0.23	-18.62	-0.02	-0.01	-0.01
EPS (Diluted)	-2.61	-0.23	-18.62	-0.02	-0.01	-0.01
Free Cash Flow	-2.36	0.08	-14.68	-14.64	-15.01	-5.65
Free Cash Flow Per Share	-0.91	0.05	-17.64	-0.01	-	-
Gross Margin	100.00%	100.00%	-	-	100.00%	-
Operating Margin	-23.83%	-7.21%	-	-	-10292.00%	-
Profit Margin	-36.97%	-2.36%	-	-	-10453.02%	-
FCF Margin	-15.76%	0.49%	-	-	-8252.74%	-
EBITDA	-2.91	-0.47	-17.23	-21.32	-18.72	-9.76
EBITDA Margin	-19.41%	-2.98%	-	-	-10292.00%	-
EBIT	-3.57	-1.13	-17.89	-21.98	-18.72	-9.76
EBIT Margin	-23.83%	-7.21%	-	-	-10292.00%	-
Effective Tax Rate	7.01%	55.89%	0.56%	0.65%	0.69%	1.84%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q